Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1835932,t1/2,"The mean t1/2, Cmax, tmax, and AUC values for 5 of the CAPD patients were 19.5 h, 202 ng.",Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835932/),h,19.5,15959,DB00492,Fosinopril
,1835932,t1/2,"Values for 1 CAPD patient with liver dysfunction were t1/2 of 65.4 h, Cmax of 182 ng.",Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835932/),h,65.4,15960,DB00492,Fosinopril
,1835932,Cmax,"Values for 1 CAPD patient with liver dysfunction were t1/2 of 65.4 h, Cmax of 182 ng.",Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835932/),ng,182,15961,DB00492,Fosinopril
,1835932,tmax,"ml-1, tmax of 9 h, and AUC of 18.1 micrograms.h.ml-1.",Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835932/),h,9,15962,DB00492,Fosinopril
,1835932,AUC,"ml-1, tmax of 9 h, and AUC of 18.1 micrograms.h.ml-1.",Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835932/),[h·μg] / [ml],18.1,15963,DB00492,Fosinopril
,1835932,Peritoneal clearance,"Peritoneal clearance of fosinoprilat was negligible, ranging from 0.07 to 0.23 ml.min-1.",Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835932/),[ml] / [min],0.07 to 0.23,15964,DB00492,Fosinopril
,17482898,LLOQ,The LLOQ of the method down to 0.1 ng mL(-1) for fosinopril and 1.0 ng mL(-1) for fosinoprilat were identifiable and reproducible.,Development and validation of liquid chromatography-tandem mass spectrometric method for simultaneous determination of fosinopril and its active metabolite fosinoprilat in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17482898/),[ng] / [ml],0.1,26170,DB00492,Fosinopril
,17482898,LLOQ,The LLOQ of the method down to 0.1 ng mL(-1) for fosinopril and 1.0 ng mL(-1) for fosinoprilat were identifiable and reproducible.,Development and validation of liquid chromatography-tandem mass spectrometric method for simultaneous determination of fosinopril and its active metabolite fosinoprilat in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17482898/),[ng] / [ml],1.0,26171,DB00492,Fosinopril
,8522635,AUC0-24,"At steady state on day 4, AUC0-24 was 1668 +/- 476 ng.hr/mL and Cmax was 143.5 +/- 33.6 ng/mL.",Invasive pharmacodynamics of fosinopril in patients with congestive heart failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522635/),[h·ng] / [ml],1668,40754,DB00492,Fosinopril
,8522635,Cmax,"At steady state on day 4, AUC0-24 was 1668 +/- 476 ng.hr/mL and Cmax was 143.5 +/- 33.6 ng/mL.",Invasive pharmacodynamics of fosinopril in patients with congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522635/),[ng] / [ml],143.5,40755,DB00492,Fosinopril
,8522635,elimination half-life,"The mean elimination half-life of fosinoprilat was 11.3 +/- 0.7 hours, and median Tmax occurred at 3 hours, corresponding to maximum plasma ACE inhibition.",Invasive pharmacodynamics of fosinopril in patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522635/),h,11.3,40756,DB00492,Fosinopril
,8522635,Tmax,"The mean elimination half-life of fosinoprilat was 11.3 +/- 0.7 hours, and median Tmax occurred at 3 hours, corresponding to maximum plasma ACE inhibition.",Invasive pharmacodynamics of fosinopril in patients with congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522635/),h,3,40757,DB00492,Fosinopril
,10510149,Cmax,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[ng] / [ml],387,77454,DB00492,Fosinopril
,10510149,Cmax,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[ng] / [ml],324,77455,DB00492,Fosinopril
,10510149,tmax,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),h,3.5,77456,DB00492,Fosinopril
,10510149,tmax,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),h,3.0,77457,DB00492,Fosinopril
,10510149,AUC,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[h·ng] / [ml],3510,77458,DB00492,Fosinopril
,10510149,AUC,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[h·ng] / [ml],2701,77459,DB00492,Fosinopril
,10510149,CUE,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),%,5.08,77460,DB00492,Fosinopril
,10510149,CUE,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),%,7.40,77461,DB00492,Fosinopril
,10510149,Cmax,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[ng] / [ml],517,77462,DB00492,Fosinopril
,10510149,Cmax,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[ng] / [ml],357,77463,DB00492,Fosinopril
,10510149,tmax,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),h,3.0,77464,DB00492,Fosinopril
,10510149,AUC,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[h·ng] / [ml],4098,77465,DB00492,Fosinopril
,10510149,AUC,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[h·ng] / [ml],2872,77466,DB00492,Fosinopril
,10510149,CUE,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),%,6.81,77467,DB00492,Fosinopril
,10510149,CUE,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),%,8.10,77468,DB00492,Fosinopril
,10510149,AI,AI=1. 17+/-0.33 vs 1.06+/-0.23 (P=0.29).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),,1. 17,77469,DB00492,Fosinopril
,10510149,AI,AI=1. 17+/-0.33 vs 1.06+/-0.23 (P=0.29).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),,1.06,77470,DB00492,Fosinopril
,25875586,total run time,Chromatographic separation was achieved on a Welch Ultimate XB-C18 column using gradient elution with a total run time of 5min.,Simultaneous quantification of fosinopril and its active metabolite fosinoprilat in rat plasma by UFLC-MS/MS: Application of formic acid in the stabilization of an ester-containing drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25875586/),min,5,77558,DB00492,Fosinopril
>,25875586,recoveries,Assay recoveries were high (>95% for fosinopril and >91% for fosinoprilat) and matrix effect was negligible.,Simultaneous quantification of fosinopril and its active metabolite fosinoprilat in rat plasma by UFLC-MS/MS: Application of formic acid in the stabilization of an ester-containing drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25875586/),%,95,77559,DB00492,Fosinopril
>,25875586,recoveries,Assay recoveries were high (>95% for fosinopril and >91% for fosinoprilat) and matrix effect was negligible.,Simultaneous quantification of fosinopril and its active metabolite fosinoprilat in rat plasma by UFLC-MS/MS: Application of formic acid in the stabilization of an ester-containing drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25875586/),%,91,77560,DB00492,Fosinopril
,11563407,AUC0-T,"Following oral administration of 10 mg fosinopril, AUC0-T and AUCinf were 1,556 +/- 586 ng x hr/mL and 1,636 +/- 620 ng x hr/mL, respectively; T 1/2 was 17.4 +/- 11.4 hr; Cmax was 183.4 +/- 59.4 ng/mL; and median Tmax was 4.0 hr, with > 99% protein binding.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),[h·ng] / [ml],"1,556",79442,DB00492,Fosinopril
,11563407,AUCinf,"Following oral administration of 10 mg fosinopril, AUC0-T and AUCinf were 1,556 +/- 586 ng x hr/mL and 1,636 +/- 620 ng x hr/mL, respectively; T 1/2 was 17.4 +/- 11.4 hr; Cmax was 183.4 +/- 59.4 ng/mL; and median Tmax was 4.0 hr, with > 99% protein binding.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),[h·ng] / [ml],"1,636",79443,DB00492,Fosinopril
,11563407,T 1/2,"Following oral administration of 10 mg fosinopril, AUC0-T and AUCinf were 1,556 +/- 586 ng x hr/mL and 1,636 +/- 620 ng x hr/mL, respectively; T 1/2 was 17.4 +/- 11.4 hr; Cmax was 183.4 +/- 59.4 ng/mL; and median Tmax was 4.0 hr, with > 99% protein binding.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),h,17.4,79444,DB00492,Fosinopril
,11563407,Cmax,"Following oral administration of 10 mg fosinopril, AUC0-T and AUCinf were 1,556 +/- 586 ng x hr/mL and 1,636 +/- 620 ng x hr/mL, respectively; T 1/2 was 17.4 +/- 11.4 hr; Cmax was 183.4 +/- 59.4 ng/mL; and median Tmax was 4.0 hr, with > 99% protein binding.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),[ng] / [ml],183.4,79445,DB00492,Fosinopril
,11563407,Tmax,"Following oral administration of 10 mg fosinopril, AUC0-T and AUCinf were 1,556 +/- 586 ng x hr/mL and 1,636 +/- 620 ng x hr/mL, respectively; T 1/2 was 17.4 +/- 11.4 hr; Cmax was 183.4 +/- 59.4 ng/mL; and median Tmax was 4.0 hr, with > 99% protein binding.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),h,4.0,79446,DB00492,Fosinopril
,11563407,AUC0-T,"Following IV administration of 7.5 mg fosinoprilat, AUC0-T and AUCinf were 7,727 +/- 2,638 ng x hr/mL and 7,816 +/- 2,693 ng x hr/mL, respectively; T 1/2 was 13.0 +/- 5.2 hr; and median Tmax was 4.0 hr, with 99.5% +/- 0.22% protein binding and a Vss of 5,850 +/- 2,780 mL.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),[h·ng] / [ml],"7,727",79447,DB00492,Fosinopril
,11563407,AUCinf,"Following IV administration of 7.5 mg fosinoprilat, AUC0-T and AUCinf were 7,727 +/- 2,638 ng x hr/mL and 7,816 +/- 2,693 ng x hr/mL, respectively; T 1/2 was 13.0 +/- 5.2 hr; and median Tmax was 4.0 hr, with 99.5% +/- 0.22% protein binding and a Vss of 5,850 +/- 2,780 mL.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),[h·ng] / [ml],"7,816",79448,DB00492,Fosinopril
,11563407,T 1/2,"Following IV administration of 7.5 mg fosinoprilat, AUC0-T and AUCinf were 7,727 +/- 2,638 ng x hr/mL and 7,816 +/- 2,693 ng x hr/mL, respectively; T 1/2 was 13.0 +/- 5.2 hr; and median Tmax was 4.0 hr, with 99.5% +/- 0.22% protein binding and a Vss of 5,850 +/- 2,780 mL.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),h,13.0,79449,DB00492,Fosinopril
,11563407,Tmax,"Following IV administration of 7.5 mg fosinoprilat, AUC0-T and AUCinf were 7,727 +/- 2,638 ng x hr/mL and 7,816 +/- 2,693 ng x hr/mL, respectively; T 1/2 was 13.0 +/- 5.2 hr; and median Tmax was 4.0 hr, with 99.5% +/- 0.22% protein binding and a Vss of 5,850 +/- 2,780 mL.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),h,4.0,79450,DB00492,Fosinopril
,11563407,Vss,"Following IV administration of 7.5 mg fosinoprilat, AUC0-T and AUCinf were 7,727 +/- 2,638 ng x hr/mL and 7,816 +/- 2,693 ng x hr/mL, respectively; T 1/2 was 13.0 +/- 5.2 hr; and median Tmax was 4.0 hr, with 99.5% +/- 0.22% protein binding and a Vss of 5,850 +/- 2,780 mL.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),ml,"5,850",79451,DB00492,Fosinopril
,11563407,Bioavailability,Bioavailability was 22.3% +/- 7.9%.,Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),%,22.3,79452,DB00492,Fosinopril
,11563407,Percent urinary excretion,Percent urinary excretion was 7.6% +/- 2.6% after oral dosing and 42.6% +/- 6.1% after IV dosing.,Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),%,7.6,79453,DB00492,Fosinopril
,11563407,Percent urinary excretion,Percent urinary excretion was 7.6% +/- 2.6% after oral dosing and 42.6% +/- 6.1% after IV dosing.,Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),%,42.6,79454,DB00492,Fosinopril
,11563407,total clearance,"After IV, dosing total clearance was 1,088 +/- 439 mL/hr, renal clearance was 472 +/- 213 mL/hr, and nonrenal clearance was 617 +/- 246 mL/hr.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),[ml] / [h],"1,088",79455,DB00492,Fosinopril
,11563407,renal clearance,"After IV, dosing total clearance was 1,088 +/- 439 mL/hr, renal clearance was 472 +/- 213 mL/hr, and nonrenal clearance was 617 +/- 246 mL/hr.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),[ml] / [h],472,79456,DB00492,Fosinopril
,11563407,nonrenal clearance,"After IV, dosing total clearance was 1,088 +/- 439 mL/hr, renal clearance was 472 +/- 213 mL/hr, and nonrenal clearance was 617 +/- 246 mL/hr.",Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563407/),[ml] / [h],617,79457,DB00492,Fosinopril
,7751424,maximum observed plasma concentrations,Mean (+/- SD) maximum observed plasma concentrations of fosinoprilat in the healthy subjects were 112.0 +/- 67.2 ng/mL after the first dose and 144.1 +/- 61.7 ng/mL at steady-state.,Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751424/),[ng] / [ml],112.0,86554,DB00492,Fosinopril
,7751424,maximum observed plasma concentrations,Mean (+/- SD) maximum observed plasma concentrations of fosinoprilat in the healthy subjects were 112.0 +/- 67.2 ng/mL after the first dose and 144.1 +/- 61.7 ng/mL at steady-state.,Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751424/),[ng] / [ml],144.1,86555,DB00492,Fosinopril
,7751424,area under the serum concentration versus time curve,The area under the serum concentration versus time curve for healthy volunteers was 790.7 +/- 431.0 ng.hr/mL after the first dose and 940.3 +/- 400.4 ng.hr/mL at steady-state.,Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751424/),[h·ng] / [ml],790.7,86556,DB00492,Fosinopril
,7751424,area under the serum concentration versus time curve,The area under the serum concentration versus time curve for healthy volunteers was 790.7 +/- 431.0 ng.hr/mL after the first dose and 940.3 +/- 400.4 ng.hr/mL at steady-state.,Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751424/),[h·ng] / [ml],940.3,86557,DB00492,Fosinopril
,7751424,first dose,"Similar values were noted in hepatically impaired patients: 926.0 +/- 293.9 ng.hr/mL and 1,255.4 +/- 434.0 ng.hr/mL for first dose and steady-state, respectively.",Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751424/),[h·ng] / [ml],926.0,86558,DB00492,Fosinopril
,7751424,first dose,"Similar values were noted in hepatically impaired patients: 926.0 +/- 293.9 ng.hr/mL and 1,255.4 +/- 434.0 ng.hr/mL for first dose and steady-state, respectively.",Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751424/),[h·ng] / [ml],"1,255.4",86559,DB00492,Fosinopril
,7751424,steady-state,"Similar values were noted in hepatically impaired patients: 926.0 +/- 293.9 ng.hr/mL and 1,255.4 +/- 434.0 ng.hr/mL for first dose and steady-state, respectively.",Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751424/),[h·ng] / [ml],"1,255.4",86560,DB00492,Fosinopril
,2967089,recovery,"3 After the intravenous dose of SQ 27, 519, the 0 to 96 h recovery of radioactivity averaged 44 and 46% of the dose in urine and faeces, respectively, indicating substantial biliary secretion.",Disposition of fosinopril sodium in healthy subjects. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967089/),%,44,105954,DB00492,Fosinopril
,2967089,recovery,"3 After the intravenous dose of SQ 27, 519, the 0 to 96 h recovery of radioactivity averaged 44 and 46% of the dose in urine and faeces, respectively, indicating substantial biliary secretion.",Disposition of fosinopril sodium in healthy subjects. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967089/),%,46,105955,DB00492,Fosinopril
,2967089,oral absorption,"5 For the solution and capsule doses, respectively, the oral absorption of fosinopril sodium averaged 32% and 36% and the oral bioavailability of SQ 27, 519 averaged 25% and 29%.",Disposition of fosinopril sodium in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967089/),%,32,105956,DB00492,Fosinopril
,2967089,oral absorption,"5 For the solution and capsule doses, respectively, the oral absorption of fosinopril sodium averaged 32% and 36% and the oral bioavailability of SQ 27, 519 averaged 25% and 29%.",Disposition of fosinopril sodium in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967089/),%,36,105957,DB00492,Fosinopril
,2967089,oral bioavailability,"5 For the solution and capsule doses, respectively, the oral absorption of fosinopril sodium averaged 32% and 36% and the oral bioavailability of SQ 27, 519 averaged 25% and 29%.",Disposition of fosinopril sodium in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967089/),%,25,105958,DB00492,Fosinopril
,2967089,oral bioavailability,"5 For the solution and capsule doses, respectively, the oral absorption of fosinopril sodium averaged 32% and 36% and the oral bioavailability of SQ 27, 519 averaged 25% and 29%.",Disposition of fosinopril sodium in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967089/),%,29,105959,DB00492,Fosinopril
,2967089,clearance,"The average values for clearance (39 ml min-1), renal clearance (17 ml min-1), Vss (10 1), and plasma protein binding (approximately 95%), indicated that SQ 27, 519 was slowly cleared from the body and not distributed extensively into extravascular sites.",Disposition of fosinopril sodium in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967089/),[ml] / [min],39,105960,DB00492,Fosinopril
,2967089,renal clearance,"The average values for clearance (39 ml min-1), renal clearance (17 ml min-1), Vss (10 1), and plasma protein binding (approximately 95%), indicated that SQ 27, 519 was slowly cleared from the body and not distributed extensively into extravascular sites.",Disposition of fosinopril sodium in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967089/),[ml] / [min],17,105961,DB00492,Fosinopril
,2967089,Vss,"The average values for clearance (39 ml min-1), renal clearance (17 ml min-1), Vss (10 1), and plasma protein binding (approximately 95%), indicated that SQ 27, 519 was slowly cleared from the body and not distributed extensively into extravascular sites.",Disposition of fosinopril sodium in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967089/),1,10,105962,DB00492,Fosinopril
,1971582,E,The high intrinsic capability of the gut and liver to hydrolyze FS was reflected by E values which ranged from 69 to 91%.,"Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971582/),%,69 to 91,134682,DB00492,Fosinopril
,1971582,body clearance,"Based on the body clearance of FS (approximately 30 ml/min/kg) estimated after the intra-arterial route, roughly 50% of the systemic hydrolysis of the prodrug appears to occur at extrahepatic site(s), such as the kidney.","Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971582/),[ml] / [kg·min],30,134683,DB00492,Fosinopril
,33352616,recovery,Solid-phase extraction technique employing Waters Oasis SPE cartridges gave clean samples with very high recovery of 97%.,A sensitive and efficient LC-MS/MS method for the bioanalysis of fosinopril diacid from human plasma and its application for a bioequivalence study in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352616/),%,97,139877,DB00492,Fosinopril
,2144379,Recovery efficiencies,Recovery efficiencies ranged from 97.2 to 109.4%.,"A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2144379/),%,97.2 to,145680,DB00492,Fosinopril
,2144379,Recovery efficiencies,Recovery efficiencies ranged from 97.2 to 109.4%.,"A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2144379/),%,109,145681,DB00492,Fosinopril
,2144379,Cross-reactivities,"Cross-reactivities for prodrug (SQ 28,555) and phenolic SQ 27,519 were 5 and 9%, respectively.","A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2144379/),%,5,145682,DB00492,Fosinopril
,2144379,Cross-reactivities,"Cross-reactivities for prodrug (SQ 28,555) and phenolic SQ 27,519 were 5 and 9%, respectively.","A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2144379/),%,9,145683,DB00492,Fosinopril
,9549638,total clearance (Clt),"The total clearance (Clt), renal clearance (ClT), and nonrenal clearance (ClNR) were significantly lower in Chinese (16.29 +/- 6.92, 6.85 +/- 2.97, and 9.44 +/- 5.08 mL.hr-1.kg-1) than those obtained in whites (29.88 +/- 6.36, 13.55 +/- 3.45, and 16.33 +/- 5.07 mL.hr-1.kg-1).",Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [h·kg],16.29,166831,DB00492,Fosinopril
,9549638,total clearance (Clt),"The total clearance (Clt), renal clearance (ClT), and nonrenal clearance (ClNR) were significantly lower in Chinese (16.29 +/- 6.92, 6.85 +/- 2.97, and 9.44 +/- 5.08 mL.hr-1.kg-1) than those obtained in whites (29.88 +/- 6.36, 13.55 +/- 3.45, and 16.33 +/- 5.07 mL.hr-1.kg-1).",Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [h·kg],29.88,166832,DB00492,Fosinopril
,9549638,renal clearance (ClT),"The total clearance (Clt), renal clearance (ClT), and nonrenal clearance (ClNR) were significantly lower in Chinese (16.29 +/- 6.92, 6.85 +/- 2.97, and 9.44 +/- 5.08 mL.hr-1.kg-1) than those obtained in whites (29.88 +/- 6.36, 13.55 +/- 3.45, and 16.33 +/- 5.07 mL.hr-1.kg-1).",Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [h·kg],6.85,166833,DB00492,Fosinopril
,9549638,renal clearance (ClT),"The total clearance (Clt), renal clearance (ClT), and nonrenal clearance (ClNR) were significantly lower in Chinese (16.29 +/- 6.92, 6.85 +/- 2.97, and 9.44 +/- 5.08 mL.hr-1.kg-1) than those obtained in whites (29.88 +/- 6.36, 13.55 +/- 3.45, and 16.33 +/- 5.07 mL.hr-1.kg-1).",Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [h·kg],9.44,166834,DB00492,Fosinopril
,9549638,renal clearance (ClT),"The total clearance (Clt), renal clearance (ClT), and nonrenal clearance (ClNR) were significantly lower in Chinese (16.29 +/- 6.92, 6.85 +/- 2.97, and 9.44 +/- 5.08 mL.hr-1.kg-1) than those obtained in whites (29.88 +/- 6.36, 13.55 +/- 3.45, and 16.33 +/- 5.07 mL.hr-1.kg-1).",Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [h·kg],29.88,166835,DB00492,Fosinopril
,9549638,renal clearance (ClT),"The total clearance (Clt), renal clearance (ClT), and nonrenal clearance (ClNR) were significantly lower in Chinese (16.29 +/- 6.92, 6.85 +/- 2.97, and 9.44 +/- 5.08 mL.hr-1.kg-1) than those obtained in whites (29.88 +/- 6.36, 13.55 +/- 3.45, and 16.33 +/- 5.07 mL.hr-1.kg-1).",Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [h·kg],13.55,166836,DB00492,Fosinopril
,9549638,nonrenal clearance (ClNR),"The total clearance (Clt), renal clearance (ClT), and nonrenal clearance (ClNR) were significantly lower in Chinese (16.29 +/- 6.92, 6.85 +/- 2.97, and 9.44 +/- 5.08 mL.hr-1.kg-1) than those obtained in whites (29.88 +/- 6.36, 13.55 +/- 3.45, and 16.33 +/- 5.07 mL.hr-1.kg-1).",Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [h·kg],9.44,166837,DB00492,Fosinopril
,9549638,nonrenal clearance (ClNR),"The total clearance (Clt), renal clearance (ClT), and nonrenal clearance (ClNR) were significantly lower in Chinese (16.29 +/- 6.92, 6.85 +/- 2.97, and 9.44 +/- 5.08 mL.hr-1.kg-1) than those obtained in whites (29.88 +/- 6.36, 13.55 +/- 3.45, and 16.33 +/- 5.07 mL.hr-1.kg-1).",Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [h·kg],16.33,166838,DB00492,Fosinopril
,9549638,volume of distribution (Vc [volume of distribution of central compartment],The Chinese subjects had a significantly lower volume of distribution (Vc [volume of distribution of central compartment] and Vdss [volume of distribution at steady state]) (29.38 +/- 21.12 and 73.67 +/- 40.20 mL/kg) than white men (58.14 +/- 15.01 and 152.49 +/- 24.89 mL/kg).,Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [kg],29.38,166839,DB00492,Fosinopril
,9549638,volume of distribution (Vc [volume of distribution of central compartment],The Chinese subjects had a significantly lower volume of distribution (Vc [volume of distribution of central compartment] and Vdss [volume of distribution at steady state]) (29.38 +/- 21.12 and 73.67 +/- 40.20 mL/kg) than white men (58.14 +/- 15.01 and 152.49 +/- 24.89 mL/kg).,Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [kg],73.67,166840,DB00492,Fosinopril
,9549638,volume of distribution (Vc [volume of distribution of central compartment],The Chinese subjects had a significantly lower volume of distribution (Vc [volume of distribution of central compartment] and Vdss [volume of distribution at steady state]) (29.38 +/- 21.12 and 73.67 +/- 40.20 mL/kg) than white men (58.14 +/- 15.01 and 152.49 +/- 24.89 mL/kg).,Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [kg],58.14,166841,DB00492,Fosinopril
,9549638,Vdss [volume of distribution at steady state],The Chinese subjects had a significantly lower volume of distribution (Vc [volume of distribution of central compartment] and Vdss [volume of distribution at steady state]) (29.38 +/- 21.12 and 73.67 +/- 40.20 mL/kg) than white men (58.14 +/- 15.01 and 152.49 +/- 24.89 mL/kg).,Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [kg],73.67,166842,DB00492,Fosinopril
,9549638,Vdss [volume of distribution at steady state],The Chinese subjects had a significantly lower volume of distribution (Vc [volume of distribution of central compartment] and Vdss [volume of distribution at steady state]) (29.38 +/- 21.12 and 73.67 +/- 40.20 mL/kg) than white men (58.14 +/- 15.01 and 152.49 +/- 24.89 mL/kg).,Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [kg],58.14,166843,DB00492,Fosinopril
,9549638,Vdss [volume of distribution at steady state],The Chinese subjects had a significantly lower volume of distribution (Vc [volume of distribution of central compartment] and Vdss [volume of distribution at steady state]) (29.38 +/- 21.12 and 73.67 +/- 40.20 mL/kg) than white men (58.14 +/- 15.01 and 152.49 +/- 24.89 mL/kg).,Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),[ml] / [kg],152.49,166844,DB00492,Fosinopril
,9549638,half-lives,The respective half-lives in Chinese and whites were 5.51 +/- 1.53 and 8.24 +/- 1.99 hours.,Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),h,5.51,166845,DB00492,Fosinopril
,9549638,half-lives,The respective half-lives in Chinese and whites were 5.51 +/- 1.53 and 8.24 +/- 1.99 hours.,Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549638/),h,8.24,166846,DB00492,Fosinopril
,8112372,maximum concentration (Cmax),"Mean maximum concentration (Cmax), clearance (CL), volume of distribution at steady-state (Vss), mean residence time (MRTiv), and t1/2 values after IV administration of 14C-fosinoprilat were 2,042 micrograms.",The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112372/),μg,"2,042",187992,DB00492,Fosinopril
,8112372,Cmax,"Following oral administration of 14C-fosinopril, mean Cmax, time to maximum plasma concentration (tmax), and fosinoprilat bioavailability values were 197 ng.ml-1, 5.2 h and 29.2%.",The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112372/),[ng] / [ml],197,187993,DB00492,Fosinopril
,8112372,time to maximum plasma concentration (tmax),"Following oral administration of 14C-fosinopril, mean Cmax, time to maximum plasma concentration (tmax), and fosinoprilat bioavailability values were 197 ng.ml-1, 5.2 h and 29.2%.",The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112372/),h,5.2,187994,DB00492,Fosinopril
,8112372,bioavailability,"Following oral administration of 14C-fosinopril, mean Cmax, time to maximum plasma concentration (tmax), and fosinoprilat bioavailability values were 197 ng.ml-1, 5.2 h and 29.2%.",The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112372/),%,29.2,187995,DB00492,Fosinopril
,8112372,Emax,"Emax ranged from 95.3 to 102.5%, and IC50 (the fosinoprilat concentration required to produce 50% of Emax) ranged from 2.6 to 4.2 ng.",The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112372/),%,95.3 to 102.5,187996,DB00492,Fosinopril
,8112372,IC50,"Emax ranged from 95.3 to 102.5%, and IC50 (the fosinoprilat concentration required to produce 50% of Emax) ranged from 2.6 to 4.2 ng.",The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112372/),ng,2.6 to 4.2,187997,DB00492,Fosinopril
,2203579,Absorption,"Absorption of the active diacids is generally poor, and moderate (typically 30 to 70%) for the prodrugs.",Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,30 to 70,223514,DB00492,Fosinopril
,2203579,bioavailability,The bioavailability of lisinopril is about 25%.,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,25,223515,DB00492,Fosinopril
,2203579,Half-lives of accumulation,Half-lives of accumulation are of the order of 12 hours; protein binding varies from little (lisinopril) to 90% (benazeprilat).,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),h,12,223516,DB00492,Fosinopril
,2203579,protein binding,Half-lives of accumulation are of the order of 12 hours; protein binding varies from little (lisinopril) to 90% (benazeprilat).,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,90,223517,DB00492,Fosinopril
,8529331,Absolute bioavailability,Absolute bioavailability was approximately 29%.,Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529331/),%,29,249170,DB00492,Fosinopril
,8529331,protein binding,"Vss was similar, and protein binding was 99% in both groups.",Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529331/),%,99,249171,DB00492,Fosinopril
,8529331,time to reach Cmax,"Median time to reach Cmax occurred at 4 hours in each group and corresponded to maximum angiotensin converting enzyme inhibition, which was essentially complete through 12 hours and markedly reduced through 24 hours.",Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529331/),h,4,249172,DB00492,Fosinopril
